Castle biosciences reports second quarter 2025 results

Delivered q2 2025 revenue of $86 million q 2 2025 total test reports for our core revenue drivers (decisiondx ® -melanoma, tissuecypher ® ) increased 33% over q 2 2024 raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million conference call and webcast today at 4:30 p.m. et friendswood, texas, aug. 04, 2025 (globe newswire) -- castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended june 30, 2025.
CSTL Ratings Summary
CSTL Quant Ranking